Hey everyone, I'm Michael Zephr leading healthcare AI initiatives at NVIDIA. Pancreatic cancer is the third leading cause of cancer deaths in America. 80 to 85% of cases are diagnosed too late for effective treatment.But what if AI could help detect these deadly tumors earlier. Enter PANTS, the world's largest pancreatic tumor data set. 23 radiologists spent years annotating over 36,000 CT scans from 145 hospitals worldwide.Not just tumors, but 24 surrounding organs to give AI complete anatomical context. T ...

Healthcare & Technology - LumineticsCore 使用自主 AI 技术来及早发现糖尿病眼病，从而为数百万人保护视力 [1] - 该技术旨在避免为时过晚的情况，具有重要的现实意义 [1] Impact - 该技术旨在对技术产生现实影响，并帮助人们建设更美好的未来 [1]

For the layman ear, which most of us obviously are. How this test works and why you exclude breast cancer and prostate cancer. Sure.And let's talk about the problem. The problem is that cancer is the number one cause of death among people who are under 85. That's 600,000 people a year and 2 million people are diagnosed.So it's is the number one health problem if you look at it through that lens. And today, we're screening for only four types of cancer. And there are 50 types of cancers and subtypes that we ...

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [5] - The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer [5]. Recent Offering - Lucid Diagnostics announced subscription agreements to sell 13,939,331 shares of common stock at a price of $1.10 per share, expecting gross proceeds of approximately $15.3 million [1]. - The offering is being managed by Canaccord Genuity as the sole placement agent, with the closing expected around March 5, 2025, subject to customary conditions [2]. Use of Proceeds - The net proceeds from the offering will be used for working capital and other general corporate purposes [2]. Regulatory Information - The securities are being offered under a registration statement on Form S-3, which was declared effective by the SEC on December 6, 2022 [3]. - A prospectus supplement will be filed with the SEC regarding the securities being offered [3]. Product Information - Lucid's EsoGuard® Esophageal DNA Test is designed for early detection of esophageal precancer in at-risk patients, utilizing a noninvasive office procedure with the EsoCheck® Esophageal Cell Collection Device [5].